We have shown that transgenic CD16 on CD16Lo Vδ2 T cells did not affect cytotoxicity, supporting the notion that CD16 signifies more than a functional enhancer of Vδ2 T cell tumor killing. The gene discussed is FCGR3B; the disease is neoplasm.